Open access
Oct 2026
Real-world treatment patterns, outcomes, and burden of early progression in small cell lung cancer (SCLC) in the US.
704 Background: Treatment options for patients with SCLC are limited, and prognosis remains poor. Most patients develop resistance to or relapse after first-line (1L) therapies within the first year in both limited-stage (LS) and extensive-stage (ES). The economic burden of SCLC is not well characterized. This...
Su Zhang, Franziska Dirnberger, Sunny Ubi et al.
· JCO Oncology Practice · 0 citations